Good to think of both sides of the deal Dotterell.
Don't think that potential competition would be a significant reason to bail out though. Any company that can't meet the challenge of competition is doomed to fail eventually. A good company will have contingencies in place through funding of the development or aquisition of other products/technology and further innovation of existing ones. I thought this was the case with Cellestis.
Competing products can also impact on market penetration of the innovator product in a positive sense in circumstances where there is still significant growth potential. e.g. the huge growth in the total global market of many cardiovascular drugs has been impacted by multiple similar products in competition with each other. Some companies even competively co-market the same drug under different brands to increase their market penetration of new products. Also two or three restaurants in a good location will often do better than one alone because it creates awareness.
The example of QFT itself v's TST shows how tough it can be for even an improved competitor to penetrate the market.
CST Price at posting:
$3.47 Sentiment: Hold Disclosure: Held